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The pharmaceutical industry is approaching unsustainable
research costs to develop new drug therapies for mental
disease because of the high failure rate in clinical trials.
These failures are due to limitations of pre-clinical studies
in animal models that fail to predict the efficacy of new
drugs in human subjects. The gap between pre-clinical
trials and clinical trials is particularly difficult in complex
mental diseases such as Alzheimer’s disease because of the
complex dynamics of the brain and the multiple chemical
pathways that drugs can affect.
However, many biological mechanisms associated with
Alzheimer’s disease are now understood, and computa-
tional power and methods have reached the point for
practical modeling of pathologies of Alzheimer’s disease.
Numerical models can combine the information from
animal studies of brain circuitry with data from human
clinical trials of drug actions. Furthermore, complex
interactions of multiple receptor targets can be predicted
by a biophysical model of brain function.
We introduce numerical models of neuronal microcir-
cuitry that are associated with symptoms of Alzheimer’s
disease. The emphasis is on the dynamics of these neural
systems and how their dynamics are modified by thera-
peutic drugs. Unlike the current state-of-the-art methods
of estimating therapeutic efficacy, the computational
platform yields a significant increase in the predictive
correlation with data from clinical trials.
To develop a biophysical model for functional cognitive
performance, we implemented a conductance-based
computer model of multicompartment neuronal cell
types in a cortical brain circuit for working memory
using preclinical data on receptor pharmacology of
catecholamine and cholinergic neurotransmitters. The
pathology of Alzheimer’s disease was subsequently imple-
mented as a loss of synapses and neurons and decreased
cholinergic tone and the model as further calibrated the
model with clinical ADAS-Cog results on acetylcholines-
terase inhibitors and 5-HT6 antagonists. As an indepen-
dent validation, we reproduce clinical data showing that
ApoE genotype, implemented as a specific synapse loss
and a decline in cholinergic tone, reduces the network
performance much more in mild cognitive impairment
conditions than at later stages of Alzheimer’s disease
pathology.
As a further example, we explore the reason for the
differential effect of memantine, an NMDA subunit
selective weak inhibitor in early and late Alzheimer’s
disease pathology. The preferential inhibition of the
NMDA-NR2C/NR2D subunits that are located on inhi-
bitory interneurons compensates for the greater excita-
tory decline observed with stronger pathology.
This quantitative systems pharmacology mechanistic
disease model uses the full human pharmacology for
clinical candidates in a humanized calibrated model of
Alzheimer’s disease. Complementary to traditional ani-
mal models, the model has potential to assess the poten-
tial off-target effects of disease-modifying drugs, the
consequences of pharmacologically active unique human
metabolites, the effect of comedications and the impact
of a small number of well-described genotypes.
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